InflaRx, a Jena, Germany-based developer of new therapeutics in the field of acute and chronic inflammation, closed its double digit million Euro round B financing by completing the second of two tranches within this round.
Lead investor was the bm|t (beteiligungsmanagement thüringen gmbh).
The proceeds will enable clinical phase II development of IFX-1, the anti complement lead drug monoclonal antibody, in different acute inflammatory indications, foster pre-clinical development of IFX-2 for the treatment of selected chronic inflammatory diseases and the development of a new bedside complement activation test in collaboration with a diagnostic partner.
Led by Prof. Niels Riedemann, co-founder and CEO, and Prof. Renfeng Guo, co-founder and CSO, InflaRx has started its first phase IIa trial with IFX-1 in 2014 targeting infectious organ dysfunction in acutely site specific septic patients. In addition the company is setting up a second phase II trial preventing systemic inflammation and organ dysfunction in large scale surgery. Additional clinical programs are in the pipeline.